BHVN · NYSE · Biotechnology

Biohaven

Develops prioritized drug programs in epilepsy, immunology, and obesity.

$15.16
After-hours close−0.24 (−1.56%)
At close$15.40(−4.47%)
DateEstimateReportedSurprise
Nov 2026−$0.79
Aug 2026−$0.76−$0.91−19.6%
May 2026−$0.86−$0.88−2.3%
Mar 2026−$1.22−$1.21+0.8%
Nov 2025−$1.91−$1.64+14.1%

The latest year is open to everyone — the 35 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Jul 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Feb 2020
Nov 2019
Aug 2019
May 2019
Feb 2019
Nov 2018
Aug 2018
May 2018
Mar 2018
Nov 2017
Aug 2017
Jun 2017
May 2017
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 9, 2026−$0.79$735.6K
Aug 10, 2026−$0.76−$0.91−19.6%$490.5K
May 4, 2026−$0.86−$0.88−2.3%$267.4K
Mar 2, 2026−$1.22−$1.21+0.8%$400.0K
Nov 10, 2025−$1.91−$1.64+14.1%$375.1K

The latest year is open to everyone — the 35 quarters behind it read with an account.

Sign in
Aug 11, 2025
May 12, 2025
Mar 3, 2025
Nov 12, 2024
Aug 8, 2024
May 9, 2024
Feb 29, 2024
Nov 14, 2023
Jul 31, 2023
May 12, 2023
Mar 23, 2023
Nov 9, 2022
Aug 5, 2022
May 10, 2022
Feb 25, 2022
Nov 9, 2021
Aug 9, 2021
May 10, 2021
Mar 1, 2021
Nov 9, 2020
Aug 10, 2020
May 7, 2020
Feb 25, 2020
Nov 1, 2019
Aug 8, 2019
May 7, 2019
Feb 28, 2019
Nov 14, 2018
Aug 14, 2018
May 15, 2018
Mar 6, 2018
Nov 14, 2017
Aug 14, 2017
Jun 16, 2017
May 5, 2017